buyWeak
Paul A. Wagner bought $19k of FBRX
See Remarks at Forte Biosciences, Inc.. 29,776 shares at an average of $0.65, traded Dec 11, 2023, filed Dec 12, 2023.
Conviction score
20Value
$19k
29,776 shares
Holdings after
1,792,716
+2% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- 0Trade size$19k at market
- 0Relative to holdingsHoldings up 1.7%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying3 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001209191-23-058404, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 11, 2023 | POpen-market purchase Common Stock | +25,000 | $0.65 | $16k | 1,787,940 | Dec 12, 2023 |
| Dec 12, 2023 | POpen-market purchase Common Stock | +4,776 | $0.65 | $3,088 | 1,792,716 | Dec 12, 2023 |
Related signals
Other insiders at Forte Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 41Moderate | FBRXbuy Forte Biosciences, Inc. | Antony A Riley CHIEF FINANCIAL OFFICER | $255k 9,680 shares | +30% | |
| 42Moderate | FBRXbuy Forte Biosciences, Inc. | Antony A Riley CHIEF FINANCIAL OFFICER | $125k 22,514 shares | +273% | |
| 15Weak | FBRXbuy Forte Biosciences, Inc. | Paul A. Wagner See Remarks | $7,525 10,000 shares | +1% | |
| 20Weak | FBRXbuy Forte Biosciences, Inc. | Paul A. Wagner See Remarks | $15k 20,520 shares | +1% | |
| 25Weak | FBRXbuy Forte Biosciences, Inc. | Paul A. Wagner See Remarks | $30k 51,203 shares | +3% | |
| 10Weak | FBRXbuy Forte Biosciences, Inc. | Paul A. Wagner See Remarks | $3,220 7,366 shares | +0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.